Current systemic therapies for melanoma

Dermatologic Surgery

Volumn 40, Issue 9, 2014, Pages 948-963

  Palathinkal, Darren M ^a   Sharma, Timmie R ^a   Koon, Henry B ^b   Bordeaux, Jeremy S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; DACARBAZINE; HUMANS; IMIDAZOLES; INDOLES; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; OXIMES; PLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SULFONAMIDES; TAXOIDS;

EID: 84906812722     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1097/01.DSS.0000452626.09513.55     Document Type: Review

References (130)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212.
2. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103: 714.
3. Swetter SM, Boldrick JC, Jung SY, Egbert BM, et al. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol 2005; 125: 685.
4. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88: 1484.
5. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199.
6. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7.
7. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444.
8. Pehamberger H, Soyer HP, Steiner A, Kofler R, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 1425.
9. Grob JJ, Dreno B, de la Salmonière P, Delaunay M, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351: 1905.
10. Cascinelli N, Belli F, MacKie RM, Santinami M, et al. Effect of longterm adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358: 866.
11. Hauschild A, Weichenthal M, Balda BR, Becker JC, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003; 21: 2883.
12. Hancock BW, Wheatley K, Harris S, Ives N, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 53.
13. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin- 2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004; 22: 4474.
14. Eggermont AM, Suciu S, MacKie R, Ruka W, et al. EORTC postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189.
15. Eggermont AM, Suciu S, Santinami M, Testori A, et al; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117.
16. Hauschild A, Weichenthal M, Rass K, Linse R, et al. Efficacy of lowdose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 2010; 28: 841.
17. Hansson J, Aamdal S, Bastholt L, Brandberg Y, et al; Nordic Melanoma Cooperative Group. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with highrisk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 2011; 12: 144.
18. Kirkwood JM, Manola J, Ibrahim J, Sondak V, et al; Eastern Cooperative Oncology Group. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant highdose interferon for melanoma. Clin Cancer Res 2004; 10: 1670.
19. Pectasides D, Dafni U, Bafaloukos D, Skarlos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009; 27: 939.
20. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709.
21. Agarwala SS, Lee SJ, Flaherty LE, Smylie M, et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (intergroup trial E 1697). J Clin Oncol 2011; 29s. Abstract 8505.
22. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
23. Omholt K, Platz A, Kanter L, Ringborg U, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9: 6483.
24. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-46. (Pubitemid 46630793)
25. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14: 6821-8.
26. Cui R, Widlund HR, Feige E, Lin JY, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007; 128: 853.
27. Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16 (INK4A) and their relevance to cancer. Biochemistry 2011; 50: 5566-82.
28. Goel VK, Lazar AJF, Warneke CL, Redston MS, et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126: 154-60. (Pubitemid 43336107)
29. Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009; 4: 551-79.
30. Drugs@FDA. FDA Approved Drug Products. Silver Spring: United States Food and Drug Administration. Available from: http: //www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set-Current- Drug&ApplNo=103132&DrugName=INTRON%20A&ActiveIngred= INTERFERON%20ALFA% 2D2B&SponsorApplicant=SCHERING&ProductMktStatus= 1&goto=Search.DrugDetails Accessed June 1, 2012.
31. Smith TJ, Wagner RR. Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med 1967; 125: 559-77.
32. Field AK, Tytell AA, Lampson GP, Hilleman MR. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci U S A 1967; 58: 1005-10.
33. Jullien P, De Maeyer-Guignard J, De Maeyer E. Interferon synthesis in X-irradiated. V. Origin of mouse serum interferon induced by polyinosinic-polycytidylic acid and encephalomyocarditis virus. Infect Immun 1974; 10: 1023-8.
34. Martinez D, Lynch RJ, Meeker JB, Field AK. Macrophage dependence of poly(I: C)-induced resistance to herpes simplex virus infection in mice. Infect Immun 1980; 28: 147-53. (Pubitemid 10096782)
35. Fleit HB, Rabinovitch M. Production of interferon by in vitro derived bone marrow macrophages. Cell Immunol 1981; 57: 495-504. (Pubitemid 11056693)
36. Eloranta ML, Alm GV. Splenic marginal metallophilic macrophages and marginal zone macrophages are the major interferon-α/β producers in mice upon intravenous challenge with herpes simplex virus. Scand J Immunol 1999; 49: 391-4. (Pubitemid 29185422)
37. Shirafuji N, Matsuda S, Ogura H. Granulocytic colony-stimulating factor stimulates human mature neutrophilic granulocytes to produce interferon-alpha. Blood 1990; 75: 17-9. (Pubitemid 20031483)
38. Eloranta ML, Sandberg K, Ricciardi-Castagnoli P, Lindahl M, et al. Production of interferon alpha/beta by murine dendritic cell lines stimulated by virus and bacteria. Scand J Immunol 1997; 46: 235-41. (Pubitemid 27400227)
39. Hochrein H, Shortman K, Vremec D, Scott B, et al. Differential production of IL-12, IFN-α and IFN-γ by mouse dendritic cell subsets. J Immunol 2001; 166: 5448-55. (Pubitemid 32374165)
40. Diebold SS, Montoya M, Unger H, Alexopoulou L, et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003; 424: 324-8. (Pubitemid 36899375)
41. Colonna M, Krug A, Cella M. Interferon-producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol 2002; 14: 373-9. (Pubitemid 34327981)
42. Peter HH, Dallügge H, Zawatzky R, Euler S, et al. Human peripheral null lymphocytes. II. Producers of type I interferon upon stimulation with tumor cells, herpes simplex virus, and Corynebacterium parvum. Eur J Immunol 1980; 10: 547-55. (Pubitemid 10040253)
43. Conta BS, Powell MB, Ruddle NH. Production of lymphotoxin, IFN-γ, and IFN-α/β by murine T cell lines and clones. J Immunol 1983; 130: 2231-5. (Pubitemid 13086765)
44. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003; 112: 170.
45. Moschos SJ, Edington HD, Land SR, Rao UN, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24: 3164.
46. Chen L, Zhu Y, Zhang G, Gao C, et al. CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2. Proc Natl Acad Sci U S A 2011; 108: 18778-83.
47. Bottomley A, Coens C, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27: 2916-23.
48. Eggermont AM, Suciu S, Santinami M, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-26. (Pubitemid 351952257)
49. Daud AI, Xu C, Hwu WJ, Urbas P, et al. Pharmacokinetic/ pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 2011; 67: 657-66.
50. Drugs@FDA. FDA Approved Drug Products. United States Food and Drug Administration: Silver Spring. Available from: http://http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set-Current- Drug&ApplNo=103293&DrugName=PROLEUKIN&ActiveIngred= ALDESLEUKIN&SponsorApplicant=CHIRON&ProductMktStatus=1&goto=Search. DrugDetails Accessed June 1, 2012.
51. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161: 1169-88. (Pubitemid 15011332)
52. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105.
53. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, et al. Treatment of 283 consecutive patients withmetastaticmelanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907.
54. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6(Suppl 1): S11.
55. Eton O, Legha SS, Bedikian AY, Lee JJ, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20: 2045.
56. Sasse AD, Sasse EC, Clark LG, Ulloa L, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007: CD005413.
57. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2, 621 patients. J Clin Oncol 2007; 25: 5426.
58. Drugs@FDA. FDA Approved Drug Products. United States Food and Drug Administration: Silver Spring. Available from: http://http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set-Current- Drug&ApplNo=202429&DrugName=ZELBORAF&ActiveIngred= VEMURAFENIB&SponsorApplicant=HOFFMANN%20LA%20ROCHE&ProductMktStatus= 1&goto=Search.DrugDetails Accessed June 1, 2012.
59. Long GV, Menzies AM, Nagrial AM, Haydu LE, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239.
60. Drugs@FDA. FDA Approved Drug Products. United States Food and Drug administration: Silver Spring. Available from: http: //http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set-Current- Drug&ApplNo=125377&DrugName=YERVOY&ActiveIngred=IPILIMUMAB& SponsorApplicant=BRISTOL%20MYERS%20SQUIBB&ProductMktStatus=1&goto= Search.DrugDetails Accessed June 1, 2012.
61. Wolchok JD, Hoos A, O'Day S, Weber JS, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412.
62. Weber JS, Amin A, Minor D, Siegel J, et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011; 21: 530.
63. Margolin K, Ernstoff MS, Hamid O, Lawrence D, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13: 459-65
64. Hodi FS, O'Day SJ, McDermott DF, Weber RW, et al. Improved survival with ipilimumab in patients with metastatic melanoma.NEngl J Med 2010; 363: 711.
65. Robert C, Thomas L, Bondarenko I, O'Day S, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517.
66. Phan GQ, Attia P, Steinberg SM, White DE, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477.
67. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012; 35: 66-72.
68. Sullivan RJ, Hoshida Y, Brunet J, Tahan S, et al. A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol 2009; 27: 9003.
69. Han D, Pottin-Clemenceau C, Imro MA, Scudeletti M, et al. IL2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL2/ INFalpha biotherapy. Oncogene 1996; 12: 1015-23. (Pubitemid 26104443)
70. SabatinoM, Kim-Schulze S, PanelliMC, Stroncek D, et al. Serumvascular endothelial growth factor and fibronectin predict clinical response to highdose interleukin-2 therapy. J Clin Oncol 2009; 27: 2645-52.
71. Drugs@FDA. FDA Approved Drug Products. United States Food and Drug Administration: Silver Spring. Available from: http: // http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set-Current- Drug&ApplNo=017575&DrugName=DTIC%2DDOME&ActiveIngred= DACARBAZINE&SponsorApplicant=BAYER%20HLTHCARE&ProductMktStatus= 1&goto=Search.DrugDetails Accessed June 1, 2012.
72. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000: CD001215.
73. Stevens MF, Hickman JA, Langdon SP, Chubb D, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[ 5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846.
74. Hill GJ II, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 1984; 53: 1299-305. (Pubitemid 14198887)
75. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158.
76. Patel PM, Suciu S, Mortier L, Kruit WH, et al. EORTC Melanoma Group extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47: 1476.
77. Atkins MB. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Kirkwood JK, editor. Molecular diagnosis, prevention & therapy of melanoma. New York: Marcel Dekker; 1997, p 219.
78. Glover D, Glick JH, Weiler C, Fox K, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5: 574.
79. Glover D, Ibrahim J, Kirkwood J, Glick J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 2003; 13: 619-26. (Pubitemid 38296900)
80. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381-404.
81. Verweij J, Catimel G, Sulkes A, Sternberg C, et al. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1995; 31A(Suppl 4): S21-4.
82. Bedikian AY, Weiss GR, Legha SS, Burris HA III, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13: 2895-9.
83. Hersh EM, O'Day SJ, Ribas A, Samlowski WE, et al. Phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010; 116: 155.
84. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006; 7: 1041-53. (Pubitemid 43949942)
85. Wolff AC, Donehower RC, Carducci MK, Carducci MA, et al. Phase I study of DHA-paclitaxel, a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2003; 9: 3589-97. (Pubitemid 37169222)
86. Kefford R, Arkenau H, Brown MP, Millward M, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28: 611s. Abstract 8503.
87. Falchook GS, Long GV, Kurzrock R, Kim KB, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-901.
88. Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs 2013; 73: 1367-76.
89. Hauschild A, Grob JJ, Demidov LV, Jouary T, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
90. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma. Med Lett Drugs Ther 2013; 55: 62-3.
91. Flaherty KT, Robert C, Hersey P, Nathan P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-14.
92. Wright CJM, McCormack PL. Trametinib: first global approval. Drugs 2013; 73: 1245-54.
93. Bradley MO, Webb NL, Anthony FH, Devanesan P, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001; 7: 3229-38. (Pubitemid 32963848)
94. Bedikian AY, DeConti RC, Conry R, Agarwala S, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 2011; 22: 787-93.
95. Chapman PB, Einhorn LH, Meyers ML, Saxman S, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745.
96. Hwu WJ, Lis E, Menell JH, Panageas KS, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21: 3351.
97. Bedikian AY, Millward M, Pehamberger H, Conry R, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738.
98. Legha SS, Ring S, Papadopoulos N, Plager C, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64: 2024.
99. McClay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50: 553.
100. Margolin KA, Liu PY, Flaherty LE, Sosman JA, et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 664.
101. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2083.
102. Creagan ET, Suman VJ, Dalton RJ, Pitot HC, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999; 17: 1884.
103. Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002; 20: 420.
104. Kaufmann R, Spieth K, Leiter U, Mauch C, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005; 23: 9001.
105. Weber RW, O'Day S, Rose M, Deck R, et al. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-α-2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 2005; 23: 8992.
106. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743.
107. Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999; 17: 651.
108. Demchak PA, Mier JW, Robert NJ, O'Brien K, et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991; 9: 1821.
109. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994; 12: 1553.
110. Antoine EC, Benhammouda A, Bernard A, Youssef A, et al. Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 1997; 3(Suppl 1): S16.
111. Legha SS, Ring S, Eton O, Bedikian A, et al. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 1997; 3(Suppl 1): S9.
112. Keilholz U, Conradt C, Legha SS, Khayat D, et al. Results of interleukin-2-based treatment in advanced melanoma: a case recordbased analysis of 631 patients. J Clin Oncol 1998; 16: 2921.
113. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17: 968.
114. Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, et al; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002; 20: 1600.
115. Keilholz U, Punt CJ, Gore M, Kruit W, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 6747.
116. AtkinsMB, Hsu J, Lee S, Cohen GI, et al; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26: 5748.
117. Greger JG, Eastman SD, Zhang V, Bleam MR, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012; 11: 909-20.
118. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, et al. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol 2012; 132: 1850-9.
119. Weber JS, Flaherty KT, Infante JR, Falchook GS, et al. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. J Clin Oncol 2012; (suppl)Abstract 8510.
120. Flaherty KT, Infante JR, Daud A, Gonzalez R, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
121. Flaherty KT, Puzanov I, Kim KB, Ribas A, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809.
122. Sosman JA, Kim KB, Schuchter L, Gonzalez R, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
123. Chapman PB, Hauschild A, Robert C, Haanen JB, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507.
124. Robert C, Soria JC, Eggermont AMM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013; 49: 2968-71
125. Eggermont AMM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur J Cancer 2013; 49: 2965-7.
126. Shimanovsky A, Jethava A, Dasanu CA. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther 2013; 13: 1413-27.
127. Rubin KM. Management of primary cutaneous and metastatic melanoma. Semin Oncol Nurs 2013; 29: 195-205
128. Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PDL1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014; 89: 140-65.
129. HamidO, Robert C, Daud A, Hodi S, et al. Safety and tumor responseswith lambrolizumab (anti-pd-1) in melanoma. N Engl J Med 2013; 369: 134-44.
130. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/ S9512/C509801. J Clin Oncol 2001; 19: 2370.